Literature DB >> 26618549

Clinical outcome and adverse events associated with empiric and pre-emptive use of amphotericin B lipid complex in a single center in lebanon.

R Moghnieh1,2,3,4, I Fawaz1, A Mugharbil5, T Jisr6, D Abdallah7, A Ibrahim5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26618549     DOI： 10.1038/bmt.2015.276

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

1.  Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).

Authors:  Georgios Chamilos; Mario Luna; Russell E Lewis; Gerald P Bodey; Roy Chemaly; Jeffrey J Tarrand; Amar Safdar; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  Haematologica       Date:  2006-06-01       Impact factor: 9.941

2.  Study of renal safety in amphotericin B lipid complex-treated patients.

Authors:  Barbara D Alexander; John R Wingard
Journal:  Clin Infect Dis       Date:  2005-05-01       Impact factor: 9.079

3.  Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies.

Authors:  J Mehta; S Kelsey; P Chu; R Powles; D Hazel; U Riley; C Evans; A Newland; J Treleaven; S Singhal
Journal:  Bone Marrow Transplant       Date:  1997-07       Impact factor: 5.483

Review 4.  Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis.

Authors:  Amar Safdar; Jonathan Ma; Fouzi Saliba; Bertrand Dupont; John R Wingard; Ray Y Hachem; Gloria N Mattiuzzi; Pranatharthi H Chandrasekar; Dimitrios P Kontoyiannis; Kenneth V Rolston; Thomas J Walsh; Richard E Champlin; Issam I Raad
Journal:  Medicine (Baltimore)       Date:  2010-07       Impact factor: 1.889

5.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

6.  Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia.

Authors:  R V Fleming; H M Kantarjian; R Husni; K Rolston; J Lim; I Raad; S Pierce; J Cortes; E Estey
Journal:  Leuk Lymphoma       Date:  2001-02

Review 7.  The current role of amphotericin B lipid complex in managing systemic fungal infections.

Authors:  Patrick Chu; Shalal Sadullah
Journal:  Curr Med Res Opin       Date:  2009-12       Impact factor: 2.580

Review 8.  Amphotericin B formulations: a comparative review of efficacy and toxicity.

Authors:  Richard J Hamill
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

9.  Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

Authors:  T J Walsh; J W Hiemenz; N L Seibel; J R Perfect; G Horwith; L Lee; J L Silber; M J DiNubile; A Reboli; E Bow; J Lister; E J Anaissie
Journal:  Clin Infect Dis       Date:  1998-06       Impact factor: 9.079

10.  Prospective audit of the effectiveness of hydrocortisone premedication on drug delivery reactions following amphotericin B lipid complex *.

Authors:  Nigel O'Connor; Ann Borley
Journal:  Curr Med Res Opin       Date:  2009-03       Impact factor: 2.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.